Phase II study for the evaluation of personalized sVCD-sVTD sequential therapy using VES-13 for newly diagnosed transplant-ineligible multiple myeloma

Trial Profile

Phase II study for the evaluation of personalized sVCD-sVTD sequential therapy using VES-13 for newly diagnosed transplant-ineligible multiple myeloma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs Bortezomib (Primary) ; Cyclophosphamide (Primary) ; Dexamethasone (Primary) ; Thalidomide (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Dec 2017 Results (n=47) assessing safety and efficacy of two sequential triplet regimens to maximise the response rates and minimise potential toxicities for elderly frail multiple myeloma patients, presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
    • 07 Sep 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top